Mar 29, 2026 | Lilly's $2.75B AI Drug Deal with Insilico; Oral Psoriasis Data Reshapes Derm at AAD 2026

Eli Lilly signs $2.75B biobucks deal with Insilico Medicinefor AI-discovered oral therapeutics. AAD 2026 brings 52-week ICOTYDE, zasocitinib Phase 3 psoriasis data, and Sanofi amlitelimab Q12W dosing in atopic dermatitis. Plus HI-PEITHO PE results from ACC and Merck's WINREVAIRCADENCE proof-of-concept.Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Eli Lilly, InsilicoMedicine, AI drug discovery, ICOTYDE, icotrokinra, zasocitinib, Takeda, Johnson Johnson, Sanofi, amlitelimab, sonelokimab, MoonLake, Boston Scientific, EKOS,HI-PEITHO, pulmonary embolism, WINREVAIR, sotatercept, Merck, Angelini Pharma,Recordati, CVC Capital Partners, AAD 2026, ACC 2026, psoriasis, atopic dermatitis, hidradenitis suppurativa, orforglipron, Orca-T, Lilly